PL2536829T3 - Sposób wytwarzania wektorów adenowirusowych Ad26 - Google Patents

Sposób wytwarzania wektorów adenowirusowych Ad26

Info

Publication number
PL2536829T3
PL2536829T3 PL11703221.9T PL11703221T PL2536829T3 PL 2536829 T3 PL2536829 T3 PL 2536829T3 PL 11703221 T PL11703221 T PL 11703221T PL 2536829 T3 PL2536829 T3 PL 2536829T3
Authority
PL
Poland
Prior art keywords
production
adenoviral vectors
adenoviral
vectors
Prior art date
Application number
PL11703221.9T
Other languages
English (en)
Inventor
Alfred Luitjens
Herk Herman Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2536829T3 publication Critical patent/PL2536829T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00Tissue, human, animal or plant cell, or virus culture apparatus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02Recovery or purification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material
PL11703221.9T 2010-02-15 2011-02-14 Sposób wytwarzania wektorów adenowirusowych Ad26 PL2536829T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30455310P 2010-02-15 2010-02-15
EP10153581 2010-02-15

Publications (1)

Publication Number Publication Date
PL2536829T3 true PL2536829T3 (pl) 2016-09-30

Family

ID=42227128

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11703221.9T PL2536829T3 (pl) 2010-02-15 2011-02-14 Sposób wytwarzania wektorów adenowirusowych Ad26

Country Status (13)

Country Link
EP (1) EP2536829B1 (pl)
JP (1) JP5250155B2 (pl)
KR (1) KR101820980B1 (pl)
CN (1) CN102762721B (pl)
AU (1) AU2011214262B2 (pl)
CA (1) CA2786835C (pl)
DK (1) DK2536829T3 (pl)
EA (1) EA023816B1 (pl)
ES (1) ES2578514T3 (pl)
MX (1) MX2012007936A (pl)
NZ (1) NZ601424A (pl)
PL (1) PL2536829T3 (pl)
WO (1) WO2011098592A1 (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004292A (es) 2008-11-03 2011-05-31 Crucell Holland Bv Metodo para la produccion de vectores adenovirales.
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
CN103305417A (zh) * 2012-03-07 2013-09-18 无锡药明康德生物技术有限公司 进行蛋白生产的高产量反应器及其生产方法和应用
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
CA2867950C (en) 2012-03-22 2023-02-21 Crucell Holland B.V. Vaccine against rsv
EA039803B1 (ru) 2013-04-25 2022-03-15 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv до слияния
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
EP3122866B1 (en) 2014-03-25 2019-11-20 Terumo BCT, Inc. Passive replacement of media
KR101971808B1 (ko) * 2014-09-26 2019-04-23 베쓰 이스라엘 디코니스 메디칼 센터 인크 인간 면역 결핍 바이러스 감염에 대한 방어 면역을 유도하기 위한 방법 및 조성물
AU2015341926B2 (en) 2014-11-04 2018-09-27 Janssen Vaccines & Prevention B.V. Therapeutic HPV16 vaccines
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
DK3319633T3 (da) 2015-07-07 2021-02-01 Janssen Vaccines & Prevention Bv Vaccine mod rsv
EP3319634B1 (en) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
AU2016309743B2 (en) 2015-08-20 2019-02-07 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
AU2017248018A1 (en) 2016-04-05 2018-09-27 Janssen Vaccines & Prevention B.V. Vaccine against RSV
CN109922829A (zh) 2016-05-02 2019-06-21 扬森疫苗与预防公司 治疗性hpv疫苗组合
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
MX2018014699A (es) 2016-05-30 2019-02-28 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
JP7272965B2 (ja) 2017-06-15 2023-05-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー Hiv抗原をコードするポックスウイルスベクターおよびその使用方法
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
CN111295391B (zh) 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途
CA3079210A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
SG11202003398SA (en) 2017-10-31 2020-05-28 Janssen Vaccines & Prevention Bv Adenovirus vectors and uses thereof
EP3704138A1 (en) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
WO2022207839A2 (en) 2021-04-01 2022-10-06 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
WO1995034671A1 (en) 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
SI1445322T2 (sl) 1995-06-15 2012-10-30 Crucell Holland Bv Pakirni sistemi za humani rekombinantni adenovirus za gensko terapijo
CA2625279A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
CZ438398A3 (cs) 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
EP1760151B1 (en) 1996-11-20 2012-03-21 Crucell Holland B.V. Adenovirus compositions obtainable by an improved production and purification method
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DE69942708D1 (de) 1998-02-17 2010-10-07 Schering Corp Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
IL139040A0 (en) 1998-04-22 2001-11-25 Genvec Inc Efficient purification of adenovirus
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
CA2350890C (en) 1998-11-16 2014-07-08 Introgen Therapeutics, Inc. Aqueous compositions for long-term stable storage of adenovirus particles including uses and methods for preparing same
CA2356373A1 (fr) 1998-12-31 2000-07-13 Aventis Pharma S.A. Methode de separation de particules virales
AU774437B2 (en) 1999-02-22 2004-06-24 Transgene S.A. Method for obtaining a purified viral preparation
CA2372655C (en) 1999-05-17 2011-11-15 Crucell Holland B.V. Recombinant adenovirus having low pre-existing neutralizing activity
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP1263461A4 (en) 2000-03-07 2009-08-12 Merck & Co Inc ADENOVIRUS FORMULATIONS
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
CA2469623C (en) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
DK1506287T3 (da) 2002-05-14 2007-08-20 Merck & Co Inc Fremgangsmåder til oprensning af adenovirus
AU2003298361B2 (en) * 2002-12-17 2009-05-14 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CA2555412C (en) * 2004-02-23 2013-06-25 Crucell Holland B.V. Virus purification methods
ES2456015T3 (es) * 2004-03-05 2014-04-21 Dsm Ip Assets B.V. Procedimiento para cultivar células mediante perfusión continua y flujo tangencial alternante
NZ581306A (en) 2004-11-16 2011-03-31 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
EP1851343A2 (en) * 2005-02-11 2007-11-07 Merck and Co., Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
EP1869171B2 (en) 2005-04-11 2015-10-14 Crucell Holland B.V. Virus purification using ultrafiltration
WO2007104792A2 (en) * 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
MX2011004292A (es) * 2008-11-03 2011-05-31 Crucell Holland Bv Metodo para la produccion de vectores adenovirales.

Also Published As

Publication number Publication date
EA023816B1 (ru) 2016-07-29
JP2013519366A (ja) 2013-05-30
AU2011214262A1 (en) 2012-08-30
EP2536829A1 (en) 2012-12-26
EA201290797A1 (ru) 2013-01-30
KR20130026518A (ko) 2013-03-13
ES2578514T3 (es) 2016-07-27
AU2011214262B2 (en) 2015-05-21
KR101820980B1 (ko) 2018-01-22
CN102762721B (zh) 2015-03-11
DK2536829T3 (en) 2016-07-04
CA2786835A1 (en) 2011-08-18
JP5250155B2 (ja) 2013-07-31
MX2012007936A (es) 2012-11-22
EP2536829B1 (en) 2016-04-06
NZ601424A (en) 2014-07-25
BR112012019023A2 (pt) 2015-09-15
CA2786835C (en) 2021-08-31
WO2011098592A1 (en) 2011-08-18
CN102762721A (zh) 2012-10-31

Similar Documents

Publication Publication Date Title
PL2536829T3 (pl) Sposób wytwarzania wektorów adenowirusowych Ad26
HK1160664A1 (en) Method for the production of adenoviral vectors
EP2606127A4 (en) METHOD FOR ASSEMBLING ADENOVIRUS
LT2608541T (lt) Vidinės prognozės dekodavimo būdas
ZA201300146B (en) Process for the production of para-xylene
IL207945A0 (en) Method for the production of carbohydrates
EP2552873A4 (en) PREPARATION FOR HEXAFLUOR-2-BUTEN
EP2552874A4 (en) PROCESS FOR PREPARING HEXAFLUOR-2 BUTENE
GB201011502D0 (en) Novel process
SG10201508779UA (en) Process for the production of paraxylene
HU1000010D0 (en) Novel process
EP2558432A4 (en) METHOD FOR THE PRODUCTION OF TETRAFLUOROLEFINES
HU1000330D0 (en) Novel method
HU1000386D0 (en) Novel process
GB201009673D0 (en) Novel process
GB201009676D0 (en) Novel process
GB201009671D0 (en) Novel process
EP2530704A4 (en) PROCESS FOR PRODUCING LINED TRENCHES
HUE044066T2 (hu) Eljárás metilén-difenil-diizocianát elõállítására
EP2597178A4 (en) PROCESS FOR PRODUCING FLUORIN
HUE047042T2 (hu) Új eljárás
HK1180008A1 (zh) 用於產生 腺病毒載體的方法
PL2536681T3 (pl) Sposób wytwarzania eterokarboksylanów
PL393115A1 (pl) Sposób wytwarzania jogurtu
IL226823A (en) Method for the production of 2- (triazinylcarbonyl) sulfonanilides